Last reviewed · How we verify

low dose ruxolitinib — Competitive Intelligence Brief

low dose ruxolitinib (low dose ruxolitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor. Area: Oncology.

phase 3 JAK inhibitor JAK1 and JAK2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

low dose ruxolitinib (low dose ruxolitinib) — Beijing Friendship Hospital. Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in signaling pathways involved in inflammation and immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
low dose ruxolitinib TARGET low dose ruxolitinib Beijing Friendship Hospital phase 3 JAK inhibitor JAK1 and JAK2
Chronic- PF-06480605 150 mg SC Q4W chronic-pf-06480605-150-mg-sc-q4w Pfizer marketed Janus kinase inhibitor JAK1 and JAK2 enzymes
Rinvoq upadacitinib AbbVie Inc. marketed JAK inhibitor Janus kinase (JAK) enzymes, particularly JAK1 and JAK2
high dose ruxolitinib high dose ruxolitinib Beijing Friendship Hospital phase 3 JAK inhibitor JAK1 and JAK2
Pf-07293893 pf-07293893 Pfizer marketed JAK inhibitor Janus kinase (JAK) pathway Not available
Xeljanz Tofacitinib Citrate Pfizer marketed JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01
Xeljanz Tofacitinib Citrate Pfizer marketed JAK inhibitor Janus kinase (JAK) enzymes 2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

  1. Pfizer · 19 drugs in this class
  2. Aclaris Therapeutics, Inc. · 2 drugs in this class
  3. Beijing Friendship Hospital · 2 drugs in this class
  4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
  5. CAGE Bio Inc. · 1 drug in this class
  6. CTI BioPharma · 1 drug in this class
  7. Celgene · 1 drug in this class
  8. Fred Hutchinson Cancer Center · 1 drug in this class
  9. LEO Pharma · 1 drug in this class
  10. McMaster University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low dose ruxolitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-ruxolitinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: